Related Experiment Video
Updated: Sep 27, 2026
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
[Long-term induced effects by only one treatment with ketoconazole on rat tumoral pituitary cells (GH3/B6 strains)]
R Drouhault1, P Vacher, D Darret
1Laboratoire de Neurophysiologie, C.N.R.S.-U.R.A. n 1200, Université de Bordeaux-II.
Abstract:
Ketoconazole, an imidazole is a powerful antimycotic that has recently been used in the treatment of endocrinological and lipid metabolism disorders as well as in anti-cancer chemotherapy. When rat mammosomatotropic cells are treated for 30 hrs., this drug produces different effects depending on whether cells are normal or tumoral (GH3/B6). A dose of 10 microM had no effect in normal cells, however, in tumoral cells it had dramatic effects: (i) 50% of the cells are killed and those which survive no longer proliferate and they secrete GH but not PRL; (ii) they respond to GHRH in a dose-dependent manner, while normal cells do not under similar culture conditions; (iii) the lipid composition of the membrane is modified as indicated by the increase in arachidonic acid turn-over and the dramatic change in the distribution of its metabolites. For the moment we cannot explain these data.
Insights
Ketoconazole selectively targets tumoral cells, inhibiting proliferation and altering hormone secretion. It also modifies membrane lipid composition and enhances responses to GHRH in these cells.
Area of Science:
- Endocrinology
- Cell Biology
- Biochemistry
Context:
- Ketoconazole, an imidazole antifungal, is explored for non-antifungal applications.
- Mammosomatotropic cells (GH3/B6) are used to study drug effects on normal vs. tumoral cells.
Purpose:
- To investigate the differential effects of ketoconazole on normal and tumoral rat mammosomatotropic cells.
- To elucidate ketoconazole's impact on cell proliferation, hormone secretion, and membrane lipid metabolism.
Summary:
- Ketoconazole (10 microM) significantly impacts tumoral GH3/B6 cells, causing 50% cell death, inhibiting proliferation, and altering growth hormone (GH) and prolactin (PRL) secretion.
- Surviving tumoral cells exhibit dose-dependent responses to GHRH, unlike normal cells.
- Membrane lipid composition is modified, evidenced by increased arachidonic acid turnover and altered metabolite distribution.
Impact:
- Ketoconazole demonstrates selective toxicity towards tumoral mammosomatotropic cells.
- The drug alters cellular signaling pathways, including GHRH responsiveness and lipid metabolism.
- Findings suggest potential therapeutic applications for ketoconazole in treating specific endocrine and potentially cancerous conditions.
